

Polymers in Tissue Engineering

Organs and Tissues

- Loss
 - Accidents
 - Birth defects
 - Hereditary disorders
 - Diseases
- Current treatments
 - Transplantation of organs
 - Surgical reconstruction
 - Mechanical devices
 - Metabolic supplements

National Waiting List

As of April 2002

51,544	Kidney transplant
17,641	Liver transplant
1,253	Pancreas transplant
276	Pancreas islet cell transplant
2,530	Kidney-pancreas transplant
179	Intestine transplant
4,136	Heart transplant
208	Heart-lung transplant
3,824	Lung transplant
79,226	Total*



Median waiting times for liver transplants from 1998 to 1999, all states except Florida (FL, courtesy of the National Academy Press).

UNOS defines the transplant community to save lives through organ transplantation. UNOS.org

Transplant Trends

Waiting list candidates as of today 7:31pm	106,891
Transplants January - June 2010	14,148
Deaths January - June 2010	3,738

As of September 2010



Transplant Drawbacks

- Shortage
- Tissue mismatch
- Lifelong immunosuppression
- Graft rejection
- Drug therapy cost
- Cancer
- Cost






FDA site inspection


Pharmaceutical companies:
Excellent history

Tissue banks: no history





- Shortage of natural organs:
- Partial solutions
- Building bionic parts based on biomaterials
- Building natural organs based on body cells (tissue engineering)




Allograft (also known as homograft) (Organs, tissues, and cells) Tissue from one species transplanted to another animal of the same species (e.g., dog to dog or human to human).

Organ allografts (kidneys, liver, lung, heart, etc.) all require immediate surgical revascularization for their metabolic requirements, thereby requiring reattachment by surgical anastomosis of the major arteries and veins.

Tissues and cells do not require revascularization and can be implanted without immediately establishing a direct blood supply (heart valves, blood vessels, orthopedic tissues, skin, cornea, etc.).

Xenograft
Tissue transplanted from one species to another (e.g., pig to monkey or pig to human).

Autograft
Tissue reimplanted into the donor (e.g., use of a patient's own veins or arteries in heart bypass grafting).



REBUILDING THE TROOPS

For wounded soldiers, the military's push for regenerative medicine offers dramatic new ways to heal.

THE BATTLE For wounded soldiers, the military's push for regenerative medicine offers dramatic new ways to heal. The effort is a high-stakes, high-tech race to develop treatments that can help soldiers recover from injuries that were once considered permanent. The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers.

THE PLAYERS The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers. The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers.

THE STAKES The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers. The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers.

THE FUTURE The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers. The military's investment in regenerative medicine is one of the largest in the world, and it is expected to lead to a new era of medical care for wounded soldiers.

THE ULTIMATE BABY BOTTLE

In The Year 2525

Are artificial wombs in our future? Will it Address Hooping Fights? By Tasha M. Fowlkes

NEEDY LIVES? Hooping up the rightmost world from the future, imagine an artificial womb or custom-made womb. It's a futuristic concept, but it's one that's already being explored in the lab. The idea is to create a womb that can support a fetus for the entire duration of pregnancy. This would allow women to avoid the risks of pregnancy and the challenges of raising a child. It would also allow women to have children who are genetically identical to them, which could be useful for research and for those who want to have children but cannot have them naturally.

THE CHALLENGE The biggest challenge is to create a womb that can support a fetus for the entire duration of pregnancy. This would require a complex system of blood vessels, nerves, and other structures. It would also require a way to control the environment of the fetus, such as temperature and oxygen levels. The biggest challenge is to create a womb that can support a fetus for the entire duration of pregnancy.

THE FUTURE The biggest challenge is to create a womb that can support a fetus for the entire duration of pregnancy. This would require a complex system of blood vessels, nerves, and other structures. It would also require a way to control the environment of the fetus, such as temperature and oxygen levels. The biggest challenge is to create a womb that can support a fetus for the entire duration of pregnancy.

PROGRESS IN TISSUE ENGINEERING

By Jill Khoury-Hossein, Joseph P. Vacanti and Robert Langer

Pioneers in building living tissue report important advances over the past decade.

When it comes to building living tissue, the past decade has been a period of rapid progress. Researchers have developed new techniques for creating artificial tissues and organs, and they have begun to use these techniques to create living tissues for medical research and for clinical applications. This progress has been made possible by advances in stem cell biology, gene editing, and other technologies. The future of tissue engineering is bright, and it is expected to lead to a new era of medical care for patients with tissue damage and disease.

The difficulty of providing a blood supply has always limited the size of engineered tissues.

Building Blood Vessels

Living tissues quickly starve without the oxygen and nutrients delivered to cells by blood. So an engineering strategy to build larger tissues is to create a network of blood vessels within the tissue. This network can be created using a variety of techniques, including 3D printing, self-assembly, and other methods. The goal is to create a network of blood vessels that can deliver oxygen and nutrients to all cells in the tissue. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

CHALLENGES The biggest challenge is to create a network of blood vessels that can deliver oxygen and nutrients to all cells in the tissue. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE FUTURE The biggest challenge is to create a network of blood vessels that can deliver oxygen and nutrients to all cells in the tissue. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

COPYING NATURE'S ARCHITECTURE

THE GOAL The health and functioning of a natural tissue depend on its internal structure. Tissues are made up of multiple cell types that work together to accomplish an organ's task. In the case of the liver, that task is to filter and process blood. The liver's structure is a complex network of blood vessels and bile ducts. This structure is what allows the liver to perform its function. The goal of tissue engineering is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE CHALLENGE The biggest challenge is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE FUTURE The biggest challenge is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

Advanced Building Materials

Engineers want to reproduce the way that nature builds things because cells depend on environment. New techniques and materials are going to create cell constructs designed to copy nature's architecture.

THE GOAL The goal is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE CHALLENGE The biggest challenge is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE FUTURE The biggest challenge is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

Naturally derived materials-based cell and drug delivery systems in skin regeneration

Shu Huang*, Xiaobing Fu**

THE GOAL The goal is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE CHALLENGE The biggest challenge is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

THE FUTURE The biggest challenge is to create artificial tissues that copy the architecture of natural tissues. This is a challenging task, but it is one that is being addressed by researchers in the field of tissue engineering.

The extracellular matrix (ECM)

Biological tissues and organs consist of cells surrounded by a complex molecular framework that is known as ECM.

ECM is a complex mixture of different macromolecules, such as collagens, proteoglycans, glycoproteins, and elastin and one of its important roles is to provide tissues with the appropriate structural integrity.

Tissue Regeneration

Organization of cells into higher ordered structures

Cell-cell interactions
Cell-extracellular matrix (ECM) interactions
Cell-polymer surface interactions
Cell adhesion, growth and differentiation
Angiogenesis (vascularization) growth factors
Environmental factors

Template/scaffold

1. Materials


Biocompatible materials, biodegradable

2. Fabrication


Shape and size (nonwoven) fiber mesh, porous matrix

3. Surface modification

Cell adhesive proteins
Drug delivery




Components necessary for tissue engineering (Auger & Germain)




a) The porous structure, in which an agent (indicated by white) is released from a synthetic material into the tissue (indicated by dark brown), and produces a gradient of the agent in the tissue that surrounds the material. This porous structure can occur when an agent is released from different materials, as illustrated in b & c. Controlled release technology can provide continuous agent release from a solid material. The inset shows a scanning electron micrograph of poly(lactide-co-glycolide) microcapsules that release nerve growth factor. b) Agent delivery by release from a degradable porous scaffold, which is composed of either synthetic polymers or natural polymers, such as collagen fibers in the matrix or fibrin. c) Agent delivery from a system with microfluidic channels. The microfluidic probe channels in the right inset, the sheath of the probe in the left inset, and fibrin in the middle inset are porous microfluidic channels of higher magnification in the left inset, which is indicated by the dark blue double region in the schematic illustration. The photograph in part b is reprinted by permission from Nature Biotechnology (2007, 25).

Development of Tissue Engineered Artificial Organs







© Advanced Tissue Sciences

Advanced Tissue Sciences is one company developing spare parts for hearts, including vascular grafts (shown above) and replacement heart valves.



The interchangeable stem cell hypothesis. Primitive stem cells may exist within the bone marrow that are capable of homing to tissues that need repair or regeneration (solid lines). Likewise, progenitor cells from an adult organ, such as liver, may act as a source of reneration-competent cells for another tissue, including the bone marrow (dotted lines).





Custom-Tailored Cells to Cure Disease

APPLICATION	STATUS
<p>DISEASE MODELING Convert iPSCs derived from patients into the affected tissue type, then study disease progression and drug responses in those cells.</p>	<ul style="list-style-type: none"> Human iPSCs have already been used to generate 12 tissue types, including cells representing diverse disorders such as Parkinson's disease and diabetes Symptoms of smooth muscular atrophy and familial dysautonomia have been "treated" in cultured cells
<p>CELL THERAPY Convert iPSCs derived from a sick patient into healthy cells for transplantation into that individual.</p>	<ul style="list-style-type: none"> 10 years or more in the future iPSC-derived neurons have been transplanted into rats to treat a version of Parkinson's iPSC-derived blood progenitor cells with corrected sickle cell anemia genes cured the disease in mice

cloning of a human

The process is extremely difficult, but it also seems inevitable. *By Charles Q. Choi*

Ever since the birth of Dolly the sheep in 1996, human cloning for reproductive purposes has seemed inevitable. Notwithstanding just dubious claims of such an achievement—including one by a company backed by a UFO cult—no human clones have been made, other than those born naturally as identical twins. Despite success with other mammals, the process has proved much more difficult in humans—which may strike some people as comforting and others as disappointing.

Scientists generate clones by replacing the nucleus of an egg cell with that from another individual. They have cloned human embryos, but none has yet successfully grown past the early stage where they are solid balls of cells known as morulas—the act of transferring the nucleus may disrupt the ability of chromosomes to align properly during cell division. "Whenever you clone a new species, there's a learning curve, and with humans it's a serious challenge getting enough good-quality egg cells to learn with," says Robert Lanza of Advanced Cell Technology in Worcester, Mass., who made headlines in 2005 for first cloning human embryos. Especially tricky steps include discovering the correct timing and mix of chemicals to properly reprogram the cell.

36 SCIENTIFIC AMERICAN June 2010

creation of life

Synthetic biology remakes organisms, but can it bring inanimate matter to life? *By David Biello*

The famous Miller-Urey experiment of 1952, which created amino acids from primordial goo, remains difficult to replicate conclusively.

Rather, synthetic biology today is about modifying existing organisms. It can be seen as genetic engineering on steroids: instead of replacing one gene, synthetic biologists modify large chunks of genes or even entire genomes. The change in DNA can force organisms to churn out chemicals, fuels and even medicines. "What


42 SCIENTIFIC AMERICAN June 2010




Cloning History

- February 1997—the first cloning of a mammal, Dolly the sheep, from an adult body cell is announced.
- March 1997—President Clinton bans federal funding of human-cloning research.
- 1998-2000—Researchers clone mice, calves, goats, and pigs. A bull is "recloned" from a cloned bull.
- April 2000—Scientists find that cloning can restore body cells to a youthful state.
- October 2001—The first cloned human embryos are created at Advanced Cell Technology Lab in Worcester, MA

Cloning for Medicine

MEGAN AND MORAG
(above) were the first mammals cloned from cultured cells. That basic technique has allowed the creation of cloned sheep carrying human genes. Such animals produce milk that can be collected and processed (left) to yield therapeutic human proteins.









Drug Therapy

Small Molecules

1980s Proteins and Peptides
Cell Eng. and Genetic Eng.

1990s DNA, RNA and Cells

2000s Tissues and Organs
Tissue Eng. and Stem Cell Eng.



Autologous Myoblast Sheets may induce Self Renewing System

Girdling effect of Myoblast sheet

Infarct heart

HGF, VEGF, TB4 midkine etc.

SDF-1, CXCR4

Migration of Stem cells

Elastic Fiber

Self Renewing

Attachment Resistant Surface

High Hydrophilic Surface: PEGylated Surface

Attachment

Detachment

Adhesion Resistant Surface Nano-domain Structured Surface

Adhesion

ATP

ATP

Passive Adhesion

Active Adhesion

Deadhesion


Coil-Globule Transition of poly(N-isopropylacrylamide)

LCST (32 ° C)

DT

hydrophilic (expanded coil)

hydrophobic (contracted globule)

$$\left[\begin{array}{c} \text{CH}-\text{CH}_2 \\ | \\ \text{C}=\text{O} \\ | \\ \text{NH} \\ | \\ \text{CH}-\text{CH}_3 \\ | \\ \text{CH}_3 \end{array} \right]_n$$


Thermoresponsive Morphology Changes of Water Droplets on Thermoresponsive PIPAAm-Grafted Surfaces

10°C

37°C

Hydrated, and Expanded Hydrophilic Surface

Dehydrated, and Shrunk Hydrophobic Surface

Temperature-Responsive Polymer-Grafted Surfaces

PIPAAm

water

soluble

insoluble

hydrophilic

hydrophobic

poly(N-isopropylacrylamide) [PIPAAm]

above 32°C

below 32°C

non-adhesive

cell adhesive

Single Cell Detachment


Trypsinization

Membrane receptor

Adhesive protein


Hydrophobic

Hydrophilic



From Active Adhesion to Passive Adhesion

37°C → 20°C








Cell Sheet Engineering

Corneal Epithelium Stem Cell Deficient Disease by Oral Mucosal Cell Sheet
(Clinical Study in Japan, 2003- and Clinical Trial in France, 2007-, Cell Seed, Inc)

Esophageal Cancer ESD Surgery by Oral Mucosal Cell Sheet
(Clinical Study in Japan, 2008-)

Cardio-myopathy by Myoblast Cell Sheet
(Clinical Study in Japan, 2007-)



FIRST: Automatic Tissue Factory & Thick Tissue Evaluation System Development

Cell Processing Center (GMP) Automated Cell Culture System

Auto Culture (Developed with Hitachi)

Auto Layering (with CellSeed/Abi)

Space reduction 1/50 ~ 1/200

X 2 ~ 5 times effective full utilization

→ 100 ~ 1000 times production capability

And avoid human error by process standardization

2U · CPC requires 280 m²
Maximum 48 sheets/year · 2U ·
HR and related cost to cover
GMP manual process and human error

CSTEC package to accelerate clinical transfer to world patients

Natural Polymers for Scaffolds

- Collagen
- Hyaluronic acid
- Gelatin
- Chitosan

Porous structure by freeze-drying, porosigen, foaming

Chemical cross-linking

Weak mechanical properties

Potential immunogenicity (proteins)

Biodegradable Polymers for Scaffolds


Polyglycolide



Poly(lactide) [poly(D,L-lactide), poly(L-lactide)]



Poly(lactide-co-glycolide)



Polymeric Scaffold

Degradation rate and degradation products (toxic?)

Biocompatibility (benefit/risk ratio)

Physical properties

Surface properties

Porosity

Pore size (Cell ingrowth)

Pore structure and connectivity


Cell Interactions (adhesion, growth, differentiation)

Processibility


Shape dimension

Polymer Scaffold Processing

- Scaffold structures
 - PGA non-woven
 - PGA fiber bonding: thermal treatment, polymer coating
 - Membrane lamination
- Scaffold preparation
 - Solution casting
 - Spray casting
 - Melt molding: compressing molding
- Porous structure
 - Emulsion freeze-drying: lyophilization
 - Particulate leaching
 - Gas saturation (high pressure)
 - Phase separation
- Polymers for scaffolds
 - Polymer blending (e.g., PLGA+PEG)
 - Polymer/ceramic composite




Solvent-casting/Particulate leaching Technique




Percentage of salts to make interconnected pores?


High Pressure Gas Expansion




Gas Foaming /Salt Leaching



Phase Separation



Emulsion Freeze-drying



Surface Modification

- Plasma treatment
- Chemical (acid/base) treatment
- Grafting of cell adhesive motifs

Cell Adhesion Sequences Derived From ECM Proteins

RGD	fibronectin, collagen, fibrinogen, laminin, vitronectin
YIGSR	laminin
IKVAG	laminin
LRE	laminin
REDV	fibronectin
DGEA	collagen
VTXG	thrombospondin
VGVPAG	elastin

FDA-Approved and Commercialized Tissue-Engineered Products

Skin		Cartilage
Aprigraf®	Dermagraft®	Carticel®
Organogenesis	Advanced Tissue Science	Genzyme

Artificial Skin

- Collagen matrix
- Cell-adhesive proteins in matrix
- Morphogenic proteins
- Nutrients
- Oxygen
- Waste

Among the first products of regenerative medicine are living skin substitutes such as Organogenesis' Apligraf (left) and Vivoskin (right).

New Secrets for Youthful Skin

Health for Life

E... wrinkles... skin... health...

Blame sun and smoking for early wrinkles. What will erase these marks of time?

Hair Apparent

GONE TODAY, HAIR TOMORROW: FOLLICULAR NEOGENESIS

1. A hair follicle is formed from a stem cell in the hair bulb.
2. The stem cell divides to produce a new hair cell and a new stem cell.
3. The hair cell grows into the hair shaft and eventually sheds.
4. The stem cell remains in the hair bulb, ready to divide again.
5. The hair shaft grows back from the stem cell.

Development of Artificial Bone by Tissue Engineering

A rabbit femur bone with a missing section is held in place with braces.

Inserted polymer scaffold with demineralized bone particle (DBP).

The scaffold is slowly infiltrated by new bone.

The scaffold ultimately gets completely replaced.

The cells have their own blood supply (red and blue vessels).

The femur bone has healed.

